CA2301709C - Epitope-bearing major histocompatibility complex class ii element/immunoglobulin chimeric molecules - Google Patents

Epitope-bearing major histocompatibility complex class ii element/immunoglobulin chimeric molecules Download PDF

Info

Publication number
CA2301709C
CA2301709C CA2301709A CA2301709A CA2301709C CA 2301709 C CA2301709 C CA 2301709C CA 2301709 A CA2301709 A CA 2301709A CA 2301709 A CA2301709 A CA 2301709A CA 2301709 C CA2301709 C CA 2301709C
Authority
CA
Canada
Prior art keywords
epitope
def
molecule
protein
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2301709A
Other languages
English (en)
French (fr)
Other versions
CA2301709A1 (en
Inventor
Sofia Casares
Teodor Doru Brumeanu
Constantin Bona
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Publication of CA2301709A1 publication Critical patent/CA2301709A1/en
Application granted granted Critical
Publication of CA2301709C publication Critical patent/CA2301709C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2301709A 1997-08-19 1997-11-04 Epitope-bearing major histocompatibility complex class ii element/immunoglobulin chimeric molecules Expired - Fee Related CA2301709C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5618597P 1997-08-19 1997-08-19
US60/056,185 1997-08-19
PCT/US1997/020023 WO1999009064A1 (en) 1997-08-19 1997-11-04 Epitope-bearing major histocompatibility complex class ii element/immunoglobulin chimeric molecules

Publications (2)

Publication Number Publication Date
CA2301709A1 CA2301709A1 (en) 1999-02-25
CA2301709C true CA2301709C (en) 2011-03-01

Family

ID=22002738

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2301709A Expired - Fee Related CA2301709C (en) 1997-08-19 1997-11-04 Epitope-bearing major histocompatibility complex class ii element/immunoglobulin chimeric molecules

Country Status (5)

Country Link
EP (1) EP1007567A4 (ja)
JP (1) JP2003524369A (ja)
AU (1) AU5428598A (ja)
CA (1) CA2301709C (ja)
WO (1) WO1999009064A1 (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU729406B2 (en) 1996-03-28 2001-02-01 Johns Hopkins University, The Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6737057B1 (en) 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US20030007978A1 (en) * 1997-09-16 2003-01-09 Burrows Gregory G. Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
JP2002504342A (ja) * 1998-02-19 2002-02-12 プレジデント アンド フェローズ オブ ハーバード カレッジ 一価ｍｈｃ結合ドメイン融合タンパク質および接合体、多価ｍｈｃ結合ドメイン融合タンパク質および接合体、ならびに多量体ｍｈｃ結合ドメイン融合タンパク質および接合体、そしてそれらのための使用
FR2796953B1 (fr) * 1999-07-29 2003-10-10 Centre Nat Rech Scient Proteines recombinantes, et complexes moleculaires derives de ces proteines, analogues a des molecules impliquees dans les reponses immunitaires
CA2403432A1 (en) * 2000-03-22 2001-09-27 Corixa Corporation Immune mediators and related methods
US6811785B2 (en) 2001-05-07 2004-11-02 Mount Sinai School Of Medicine Of New York University Multivalent MHC class II—peptide chimeras
US8377447B2 (en) 2003-09-05 2013-02-19 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
CA2595462A1 (en) * 2005-01-21 2006-07-27 Nalan Utku Hla fusion molecules and uses thereof
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126433A (en) * 1986-08-21 1992-06-30 The Trustees Of Columbia University In The City Of New York Soluble forms of the t cell surface protein cd4
US5109123A (en) * 1988-06-14 1992-04-28 Dana Farber Cancer Institute Alteration of ability of soluble CD4 fragments to bind HIV
US5130297A (en) * 1988-06-23 1992-07-14 Anergen, Inc. Conjugates useful in ameliorating autoimmunity MHC-II-peptide
AU3220593A (en) 1991-11-19 1993-06-15 Anergen, Inc. Soluble mhc molecules and their uses
US5820866A (en) * 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation

Also Published As

Publication number Publication date
WO1999009064A1 (en) 1999-02-25
EP1007567A4 (en) 2005-03-16
JP2003524369A (ja) 2003-08-19
EP1007567A1 (en) 2000-06-14
CA2301709A1 (en) 1999-02-25
AU5428598A (en) 1999-03-08

Similar Documents

Publication Publication Date Title
Demotz et al. Delineation of several DR-restricted tetanus toxin T cell epitopes.
AU696664B2 (en) CTLA4 mutant molecules and uses thereof
US6811785B2 (en) Multivalent MHC class II—peptide chimeras
US6015884A (en) Soluble divalent and multivalent heterodimeric analogs of proteins
US7074905B2 (en) Soluble MHC complexes and methods of use thereof
CA2301709C (en) Epitope-bearing major histocompatibility complex class ii element/immunoglobulin chimeric molecules
WO1997035991A9 (en) Soluble divalent and multivalent heterodimeric analogs of proteins
AU728911B2 (en) Mutants of the LAG-3 proteins, products for the expression of these mutants and use
JP2905170B2 (ja) オリゴマー化ペプチド−ｍｈｃ分子複合体
NZ232203A (en) Human soluble intercellular adhesion molecule-1 (sicam-1), dna encoding it, antibodies and pharmaceutical compositions
JP2006104206A (ja) Ｃｄ１により提示される抗原の単離方法、ｃｄ１により提示される抗原から成るワクチン、および該方法に使用する細胞株
Casares et al. Engineering and characterization of a murine MHC class II-immunoglobulin chimera expressing an immunodominant CD4 T viral epitope.
Barber et al. Unusual uniformity of the N-linked oligosaccharides of HLA-A,-B, and-C glycoproteins.
US6458354B1 (en) Molecular complexes which modify immune responses
EP0286447A2 (en) Method and agents relating to prophylactic treatment of autoimmune diseases
Margulies et al. Engineering soluble major histocompatibility molecules: Why and how
JPH0847392A (ja) スギ花粉アレルゲンＣｒｙ ｊ ＩＩエピトープ
Zappacosta et al. The murine liver-specific nonclassical MHC class I molecule Q10 binds a classical peptide repertoire
Zhu et al. A recombinant single‐chain human class II MHC molecule (HLA‐DR1) as a covalently linked heterotrimer of α chain, β chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens
Meyerson et al. Functional dissociation of CD8 alpha's Ig homologue and connecting peptide domains.
JP2008545404A (ja) ポリペプチド
Gumperz et al. Specificity of two anti‐class IHLA monoclonal antibodies that block class I recognition by the NKB1 killer cell inhibitory receptor
AU770938B2 (en) Soluble divalent and multivalent heterodimeric analogs of proteins
KR100544449B1 (ko) 단백질의 가용성2가 및 다가 헤테로 이량체 유사체
Found Patent Report

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20121105